By Martin Baccardax “Our strong results reflect growth of our in-line and new product portfolios,” said CEO Giovanni Caforio. Bristol Myers Squibb (BMY) – Get Bristol-Myers Squibb Company Report shares moved higher Wednesday after it posted better than-expected third quarter earnings Wednesday, as solid gains for its blood clot treatment offset ongoing weakness for its off-patent cancer drug Revlimid. Bristol Myers said non-GAAP earnings for the three months ending in September came in at $1.99 per share, essentially flat to the same period last year but firmly ahead of the Street consensus fo…